Literature DB >> 25426568

Left ventricular dilatation and subclinical renal damage in primary hypertension.

Elena Ratto1, Francesca Viazzi, Barbara Bonino, Annalisa Gonnella, Debora Garneri, Emanuele L Parodi, Gian Paolo Bezante, Lorenzo E Derchi, Giovanna Leoncini, Roberto Pontremoli.   

Abstract

OBJECTIVE: A new classification of left ventricular geometry based on left ventricular dilatation and concentricity has recently been developed. This classification identifies subgroups differing with regard to systemic haemodynamics, left ventricular function and cardiovascular prognosis. We investigated the relationship between the new classification of left ventricular geometry and subclinical renal damage, namely urine albumin excretion and early intrarenal vascular changes in primary hypertensive patients.
METHODS: A total of 449 untreated hypertensive patients were studied. Four different patterns of left ventricular hypertrophy (eccentric nondilated, eccentric dilated, concentric nondilated and concentric dilated hypertrophy) were identified by echocardiography. Albuminuria was measured as the albumin-to-creatinine ratio. Early intrarenal vascular changes, expressed as the renal volume to resistive index ratio, were evaluated by ultrasound and Doppler scan.
RESULTS: Patients with concentric dilated left ventricular hypertrophy had higher albumin excretion rates (P = 0.0258) and prevalence of microalbuminuria (P < 0.0001) and lower renal volume to resistive index ratio than patients with concentric nondilated hypertrophy (P = 0.0093). Patients with eccentric dilated hypertrophy showed a higher prevalence of microalbuminuria than patients with eccentric nondilated hypertrophy (P < 0.0001). Moreover, patients with chamber dilatation showed a higher prevalence of microalbuminuria (P = 0.0002) and lower renal volume to resistive index ratio (P = 0.0107) than patients without chamber dilatation. After adjusting for potentially confounding variables, left ventricular chamber dilatation was an independent predictor of subclinical renal damage.
CONCLUSION: Left ventricular dilatation is associated with subclinical renal damage in hypertension. These findings extend previous reports and provide a pathophysiological rationale for the observed unfavourable prognosis in patients with left ventricular dilatation.

Entities:  

Mesh:

Year:  2015        PMID: 25426568     DOI: 10.1097/HJH.0000000000000430

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  Microalbuminuria in primary hypertension: a guide to optimal patient management?

Authors:  Francesca Viazzi; Francesca Cappadona; Roberto Pontremoli
Journal:  J Nephrol       Date:  2016-07-14       Impact factor: 3.902

2.  Metabolic syndrome is associated with left ventricular dilatation in primary hypertension.

Authors:  E Ratto; F Viazzi; D Verzola; B Bonino; A Gonnella; E L Parodi; G P Bezante; G Leoncini; R Pontremoli
Journal:  J Hum Hypertens       Date:  2015-06-25       Impact factor: 3.012

3.  Relationship between Aortic Arch Calcification, Detected by Chest X-Ray, and Renal Resistive Index in Patients with Hypertension.

Authors:  Adem Adar; Orhan Onalan; Hakan Keles; Fahri Cakan; Ugur Kokturk
Journal:  Med Princ Pract       Date:  2018-11-27       Impact factor: 1.927

Review 4.  The internist and the renal resistive index: truths and doubts.

Authors:  Maria Boddi; Fabrizia Natucci; Elisa Ciani
Journal:  Intern Emerg Med       Date:  2015-09-04       Impact factor: 3.397

Review 5.  Clinical Value of Complex Echocardiographic Left Ventricular Hypertrophy Classification Based on Concentricity, Mass, and Volume Quantification.

Authors:  Andrea Barbieri; Alessandro Albini; Anna Maisano; Gerardo De Mitri; Giovanni Camaioni; Niccolò Bonini; Francesca Mantovani; Giuseppe Boriani
Journal:  Front Cardiovasc Med       Date:  2021-04-27

Review 6.  Renal resistive index in hypertensive patients.

Authors:  Ioannis Andrikou; Costas Tsioufis; Dimitris Konstantinidis; Alexandros Kasiakogias; Kyriakos Dimitriadis; Ioannis Leontsinis; Eirini Andrikou; Elias Sanidas; Ioannis Kallikazaros; Dimitris Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-10-25       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.